Robert M. Ward

Dr. Robert M. Ward


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2013 in Pediatric Drugs
Verified
Journal Article
Open access
PDF file
RWRobert M. Ward
Robert M. Ward
GKGregory L. Kearns
Gregory L. Kearns
Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications for treatment of adults and children. Their effectiveness for treatment of peptic conditions in the pediatric population, including gastric ulcers, gastroesophageal reflux disease (GERD), and Helicobacter pylori infections has been established for children older than 1 year. Studies of the preverbal population of neonates and infants have identified doses that inhibit acid production, but the effectiveness of PPIs in the treatment of GERD has not been established except for the recent approval of esomeprazole treatment of erosive esophagitis in infants. Reasons that have been proposed for this are complex, ranging from GERD not occurring in this population to a lack of histologic identification of esophagitis related to GERD to questions about the validity of symptom scoring systems to identify esophagitis when it occurs in infants. The effectiveness of PPIs relates to their structures, which must undergo acidic activation within the parietal cell to allow the PPI to be ionized and form covalent disulfide bonds with cysteines of the H+–K+-adenosine triphosphatase (H+–K+-ATPase). Once the PPI binds to the proton pump, the pump is inactivated. Some PPIs, such as omeprazole and rabeprazole bind to cysteines that are exposed, and their binding can be reversed. After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h. Cytochrome P450 (CYP) 2C19 and to a lesser degree CYP3A4 clear the PPIs metabolically. These enzymes are immature at birth and reach adult levels of activity by 5–6 months after birth. This parallels studies of the maturation of CYP2C19 to adult levels by roughly the same age after birth. Specific single nucleotide polymorphisms of CYP2C19 reduce clearance proportionally and increase exposure and prolong proton pump inhibition. Prolonged treatment of pediatric patients with PPIs has not caused cancer or significant abnormalities.

1 January 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
RWRobert M. Ward
Robert M. Ward
DBDaniel K. Benjamin
Daniel K. Benjamin
JDJonathan M. Davis
Jonathan M. Davis
RGRichard L. Gorman
Richard L. Gorman
RKRalph Kauffman
Ralph Kauffman
Catherine SherwinCatherine Sherwin
Catherine Sherwin

20 March 2010 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
RWRobert M. Ward
Robert M. Ward
BTBrinda Tammara
Brinda Tammara
SSSandra E. Sullivan
Sandra E. Sullivan
DSDan L. Stewart
Dan L. Stewart
NRNatalie Rath
Natalie Rath
GCGail M. Comer
Gail M. Comer

1 June 2013 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CSChris Stockmann
Chris Stockmann
BFBernhard Fassl
Bernhard Fassl
RGRoger Gaedigk
Roger Gaedigk
FNFlory Nkoy
Flory Nkoy
DUDerek A. Uchida
Derek A. Uchida
RWRobert M. Ward
Robert M. Ward

1 April 2007 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
RWRobert M. Ward
Robert M. Ward
RKR Kauffman
R Kauffman

1 June 2019 in Clinics in Perinatology
Verified
Journal Article
Closed access
RWRobert M. Ward
Robert M. Ward
MVMichael W. Varner
Michael W. Varner